» Articles » PMID: 28479601

B7-DC (PD-L2) Costimulation of CD4 T-helper 1 Response Via RGMb

Overview
Date 2017 May 9
PMID 28479601
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

The role of B7-DC in T-cell responses remains controversial because both coinhibitory and costimulatory functions have been reported in various experimental systems in vitro and in vivo. In addition to interacting with the coinhibitory receptor PD-1, B7-DC has also been shown to bind repulsive guidance molecule b (RGMb). The functional consequences of the B7-DC/RGMb interaction, however, remain unclear. More than a decade ago, we reported that replacement of a murine B7-DC mutant lysine with serine (K113S) at positive 113 resulted in a loss of binding capacity to PD-1. Nevertheless, K113S remained costimulatory for T cells in vitro, implicating a dual functionality for B7-DC in T-cell responses. Here we show that recombinant K113S protein interacts with RGMb with a similar affinity to wild-type B7-DC. More importantly, K113S costimulates CD4 T-cell responses via RGMb and promotes Th1 polarization. RGMb is expressed on the surface of naive mouse T cells, macrophages, neutrophils and dendritic cells. Finally, K113S/RGMb costimulation suppresses Th2-mediated asthma and ameliorates small airway inflammation and lung pathology in an experimental mouse model. Our findings indicate that RGMb is a costimulatory receptor for B7-DC. These findings from the K113S variant provide not only a possible explanation for the B7-DC-triggered contradictory effects on T-cell responses, but also a novel approach to investigate the B7-DC/PD-1/RGMb axis. Recombinant K113S or its derivatives could potentially be developed as an agonist for RGMb to costimulate the Th1 response without triggering PD-1-mediated T-cell inhibition.

Citing Articles

PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance database.

Gerard A, Merino D, Benzaquen J, Destere A, Borchiellini D, Gosset C Front Immunol. 2025; 16:1514033.

PMID: 39911399 PMC: 11794220. DOI: 10.3389/fimmu.2025.1514033.


Immunophenotyping of T Cells in Lung Malignancies and Cryptogenic Organizing Pneumonia.

Yanagihara T, Hata K, Matsubara K, Kunimura K, Suzuki K, Tsubouchi K J Clin Med. 2025; 14(2.

PMID: 39860323 PMC: 11766438. DOI: 10.3390/jcm14020316.


Targeting RGMb interactions: Discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings.

Meira M, Frey A, Chekkat N, Rybczynska M, Sellam Z, Park J MAbs. 2024; 16(1):2432403.

PMID: 39588913 PMC: 11601088. DOI: 10.1080/19420862.2024.2432403.


PD-1 immunology in the kidneys: a growing relationship.

Chen R, Lin Q, Tang H, Dai X, Jiang L, Cui N Front Immunol. 2024; 15:1458209.

PMID: 39507530 PMC: 11537962. DOI: 10.3389/fimmu.2024.1458209.


Mechanisms of Bone Morphogenetic Protein 2 in Respiratory Diseases.

Wen Y, Zheng Y, Hua S, Li T, Bi X, Lu Q Curr Allergy Asthma Rep. 2024; 25(1):1.

PMID: 39466470 DOI: 10.1007/s11882-024-01181-7.


References
1.
Neurath M, Finotto S, Glimcher L . The role of Th1/Th2 polarization in mucosal immunity. Nat Med. 2002; 8(6):567-73. DOI: 10.1038/nm0602-567. View

2.
Xia Y, Cortez-Retamozo V, Niederkofler V, Salie R, Chen S, Samad T . Dragon (repulsive guidance molecule b) inhibits IL-6 expression in macrophages. J Immunol. 2010; 186(3):1369-76. PMC: 3670585. DOI: 10.4049/jimmunol.1002047. View

3.
Ishida M, Iwai Y, Tanaka Y, Okazaki T, Freeman G, Minato N . Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett. 2002; 84(1):57-62. DOI: 10.1016/s0165-2478(02)00142-6. View

4.
Gavett S, OHearn D, Li X, Huang S, Finkelman F, Wills-Karp M . Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med. 1995; 182(5):1527-36. PMC: 2192202. DOI: 10.1084/jem.182.5.1527. View

5.
Steinke J, Borish L . Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res. 2001; 2(2):66-70. PMC: 59570. DOI: 10.1186/rr40. View